Overview
Synoptis Pharma is an experienced Polish manufacturer of prescription and over-the-counter medicines, food supplements, medical devices and dermocosmetics. The company draws on the NEUCA Group’s 30 years of experience and offers a broad product portfolio, competitive prices and resale support.
Financials
Revenue history (in m)
From the notes
| Current income tax (CIT due) | $3,381,125 |
Filing timeliness
Financial statements were filed on time, on average 50 days early. All were audited by a statutory auditor.
- 202502/06/2026
- 202429/04/2025
- 202314/05/2024
- 202204/07/2023
- 202108/06/2022
- 202009/08/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Medical devices
- Dietary supplements
- Cosmetic products
- Biocidal products
- Medicines
- First aid kits
Websites
The company has 4 websites. Traffic on the sites is measured with Google Analytics.
- bolgardla.plStrona główna - SynoseptWordPress 7.1Google AnalyticsYoast SEOLLiteSpeed
- equil.plPoznaj mikropompę insulinową EquilGoogle Tag Manager
- erosmowy.plEROSMOWY – prawdziwe pytania. Wartościowe odpowiedzi.WordPress 6.2Google AnalyticsGoogle Tag ManagerYoast SEO
Trademarks
The company holds 193 active trademarks registered with the Polish Patent Office. 12 applications are pending. 46 marks have expired or were not registered. The first mark was filed in 2009.
| Mark | Protected until | |
|---|---|---|
| Dapheria (word) | Jan 30, 2036 | |
| HONEY TUSS (word) | Jan 30, 2036 | |
| BUPROXIL (word) | Jan 15, 2036 | |
| LISDAVEX (word) | Jan 15, 2036 | |
| TRAZOXIN (word) | Jan 15, 2036 |
Authorized Representatives
Manner of representation
The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 360,000 | $4,862,236.63 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Synoptis Industrial sp. z o.o. | 4,402,957.86 USD | 99.9985% |
Bank accounts
Registered as a VAT taxpayer on 2005-01-17.
50 1160 2202 0000 0001 6508 4398
26 1160 2202 0000 0002 4463 4336
37 1160 2202 0000 0001 1318 2648
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Consumer credit intermediary | Active | ||
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Adamed Pharma S.A. | $541,927,181.76 | adamed.com.pl | ||
| Biofarm sp. z o.o. | $143,422,260.45 | biofarm.pl | ||
| Zentiva Polska sp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Farmak International sp. z o.o. | $101,647,142.16 | farmakinternational.pl | ||
| Polfarmex S.A. | $73,543,379.32 | polfarmex.pl | ||
| Solinea sp. z o.o. | $72,245,607.27 | solinea.pl | ||
| SUN-Farm sp. z o.o. | $51,063,341.52 | sunfarm.pl | ||
| US Pharmacia sp. z o.o. | $41,267,631.19 | uspharmacia.pl | ||
| Tactica Pharmaceuticals sp. z o.o. | $28,095,609.42 | tactica.pl | ||
| Aristo Pharma sp. z o.o. | $22,775,627.72 | aristo-pharma.pl |
Change history
| Date | Event | |
|---|---|---|
| 2015-07-02 | PKD change (Removed: 57 codes; Added: 1 code) | |
| 2012-10-23 | Address change (Taśmowa 7, 02-677, Warszawa → Krakowiaków 65, 02-255, Warszawa) | |
| 2010-11-30 | Address change (Aleje Jerozolimskie 151, 02-326, Warszawa → Taśmowa 7, 02-677, Warszawa) | |
| 2010-11-30 | Share capital increase (14,000,000.00 PLN → 18,000,000.00 PLN) | |
| 2010-02-16 | Share capital increase (55,000.00 PLN → 14,000,000.00 PLN) |
FAQ
Last updated: 2026-10-07